Drug intelligence / Profile preview

TQ-B3233

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQ-B3233 is a small molecule BRAF inhibitor developed by Chia Tai Tianqing Pharmaceutical Group. It is being investigated primarily for the treatment of melanoma and other neoplasms, with its highest development phase being Phase 1 clinical trials. The drug acts by inhibiting BRAF, a serine/threonine-protein kinase involved in cell growth and proliferation pathways that are often dysregulated in cancers such as melanoma. The compound is administered orally[1][2][3].

Targets

BRAF (B-Raf proto-oncogene, serine/threonine kinase)

Beyond the preview

Go deeper on TQ-B3233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-B3233.

Explore the full profile